Advancing Preeclampsia Risk Assessment with the sFlt-1/PlGF Ratio

Published on June 30, 2026 | 10 min read

Key takeaways

Insight into the clinical evidence supporting the sFlt-1/PlGF ratio for short-term preeclampsia risk assessment and its role in practice
Practical understanding of how to interpret the Elecsys sFlt-1/PlGF ratio to help identify severe preeclampsia and potential adverse outcomes
Strategies for integrating angiogenic biomarkers with standard assessments to enhance patient monitoring, management, and resource optimization

Advancing Preeclampsia Risk Assessment

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

Advancing Preeclampsia Risk Assessment: Integrating the sFlt-1/PlGF Ratio into Clinical Practice (01:01:12)

Preeclampsia affects millions of women each year, yet predicting which patients will progress to severe outcomes remains a challenge.¹ In this session, hear from Sarosh Rana, MD, MPH; S. Ananth Karumanchi, MD; and Allyson Kozak, PhD, MBA, NRCC, who will review the clinical evidence behind the sFlt-1/PlGF ratio and demonstrate how angiogenic biomarkers are being applied in real-world care to support more informed, timely decision-making.

Contact Us

Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.

Section 1: Introduction

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

Introduction (1:57)

Provides an overview of the webinar goals, speakers, and how the sFlt‑1/PlGF ratio fits into the broader context of preeclampsia care.

Section 2: Prediction

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

Prediction (4:41)

Reviews the burden of preeclampsia and highlights the limitations of traditional assessment methods in predicting disease progression and severe outcomes.

Section 3: Biomarkers

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

Biomarkers (10:42)

Explains the biology of sFlt‑1 and PlGF, the concept of their ratio, and the evidence supporting their use in short‑term preeclampsia risk assessment.

Section 4: Implementation

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

Implementation (13:00)

Outlines practical considerations, workflows, and decision pathways for integrating the Elecsys® sFlt‑1/PlGF ratio into existing clinical and laboratory processes.

Section 5: Performance

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

Performance (11:33)

Summarizes data on how the sFlt‑1/PlGF ratio performs in real‑world clinical settings, including predictive value and impact on patient management.

Section 6: Cases

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

Cases (11:34)

Uses illustrative patient cases to demonstrate interpretation of sFlt‑1/PlGF results and their influence on clinical decision‑making in suspected preeclampsia.

Section 7: Q&A Session

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

Q&A Session (8:07)

Recaps key takeaways from the webinar and addresses participant questions about evidence, implementation, and next steps for using sFlt‑1/PlGF in practice.